BR112012001915A2 - derivado de análogo de glp-1 ou seus sais farmacêuticos e seu uso. - Google Patents

derivado de análogo de glp-1 ou seus sais farmacêuticos e seu uso.

Info

Publication number: BR112012001915A2
Authority: BR; Brazil
Prior art keywords: glp; analogue; derivative; pharmaceutical salts; pharmaceutical
Prior art date: 2009-07-30

Application number

BR112012001915A

Other languages

English (en)

Other versions

BR112012001915B1 (pt

Inventor

Aifeng Lü

Changan Sun

Hengli Yuan

Yali Wang

Original Assignee

Jiangsu Hansoh Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-30

Filing date

2010-07-29

Publication date

2016-11-08

2010-07-29 Application filed by Jiangsu Hansoh Pharmaceutical filed Critical Jiangsu Hansoh Pharmaceutical

2016-11-08 Publication of BR112012001915A2 publication Critical patent/BR112012001915A2/pt

2019-11-12 Publication of BR112012001915B1 publication Critical patent/BR112012001915B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

BR112012001915-5A 2009-07-30 2010-07-29 derivado do análogo de glp-1 ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso dos mesmos BR112012001915B1 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN2009101655599A CN101987868B (zh)	2009-07-30	2009-07-30	Glp-1类似物的衍生物或其可药用盐和用途
PCT/CN2010/075548 WO2011012080A1 (zh)	2009-07-30	2010-07-29	Glp-1类似物的衍生物或其可药用盐和用途

Publications (2)

Publication Number	Publication Date
BR112012001915A2 true BR112012001915A2 (pt)	2016-11-08
BR112012001915B1 BR112012001915B1 (pt)	2019-11-12

Family

ID=43528782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112012001915-5A BR112012001915B1 (pt)	2009-07-30	2010-07-29	derivado do análogo de glp-1 ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso dos mesmos

Country Status (16)

Country	Link
US (1)	US20120129768A1 (pt)
EP (1)	EP2460825B1 (pt)
JP (1)	JP5768048B2 (pt)
CN (2)	CN101987868B (pt)
AU (1)	AU2010278466B2 (pt)
BR (1)	BR112012001915B1 (pt)
CA (1)	CA2769229C (pt)
DK (1)	DK2460825T3 (pt)
ES (1)	ES2694394T3 (pt)
HK (1)	HK1154027A1 (pt)
MX (1)	MX2012001186A (pt)
PL (1)	PL2460825T3 (pt)
PT (1)	PT2460825T (pt)
RU (1)	RU2565536C2 (pt)
WO (1)	WO2011012080A1 (pt)
ZA (1)	ZA201200239B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102229668A (zh) *	2011-06-03	2011-11-02	浙江贝达药业有限公司	一种glp-1衍生物及其应用
CN103566354B (zh) *	2012-07-25	2017-12-05	江苏豪森药业集团有限公司	含有glp‑1类似物的衍生物或其可药用盐的药物组合物
CN103861089B (zh) *	2012-12-17	2019-06-28	江苏豪森药业集团有限公司	Glp-1类似物的衍生物或其可药用盐注射液及其制备方法和用途
US11117946B2 (en)	2016-03-23	2021-09-14	Bachem Holding Ag	Method for preparing glucagon-like peptides
TW201821434A (zh)	2016-10-10	2018-06-16	法商賽諾菲公司	製備包含親脂性修飾的離胺酸側鏈的肽的方法
CN110291099B (zh) *	2016-12-10	2024-06-21	拜康有限公司	利拉鲁肽的合成
CN108883073B (zh) *	2016-12-30	2021-10-08	江苏恒瑞医药股份有限公司	一种glp-1类似物的药物组合物及其制备方法
CN109806386A (zh) *	2017-11-20	2019-05-28	江苏恒瑞医药股份有限公司	Fxr激动剂与glp-1类似物的药物组合物和用途
CN115814063A (zh) *	2018-04-19	2023-03-21	杭州先为达生物科技有限公司	Glp-1衍生物及其治疗用途
CN113214382B (zh) *	2018-04-19	2024-01-19	杭州先为达生物科技股份有限公司	酰化的glp-1衍生物
WO2020104833A1 (en) *	2018-11-19	2020-05-28	4P-Pharma	Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
AU2020256648A1 (en) *	2019-04-11	2021-11-04	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Multi-receptor agonist and medical use thereof
CN111825758A (zh) *	2019-04-19	2020-10-27	上海翰森生物医药科技有限公司	Glp-1和gip共激动剂化合物
CN110540587B (zh) *	2019-08-30	2021-03-02	江苏诺泰澳赛诺生物制药股份有限公司	一种有效提高合成肽纯化收率的色谱方法
CN110551203B (zh) *	2019-09-25	2023-02-10	成都奥达生物科技有限公司	一种艾塞那肽类似物
CN110684082B (zh) *	2019-10-08	2021-12-10	江苏诺泰澳赛诺生物制药股份有限公司	Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CN114617956B (zh) *	2020-12-10	2023-10-03	江苏中新医药有限公司	一种高效降糖的蛋白质药物
CN114685643A (zh) *	2020-12-29	2022-07-01	苏州康宁杰瑞生物科技有限公司	一种人glp-1多肽变体及其应用
CN114685644A (zh) *	2020-12-29	2022-07-01	苏州康宁杰瑞生物科技有限公司	一种人glp-1多肽变体及其应用
AU2022386489A1 (en) *	2021-11-12	2024-05-23	Fujian Shengdi Pharmaceutical Co., Ltd.	Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
CN115785249B (zh) *	2022-10-13	2023-07-21	江苏师范大学	一类glp-1类似物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
BRPI9711437B8 (pt)	1996-08-30	2021-05-25	Novo Nordisk As	derivados de glp-1
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
JP2002508162A (ja)	1998-02-27	2002-03-19	ノボノルディスクアクティーゼルスカブ	Ｎ末端を短縮したｇｌｐ−１誘導体
WO2000041548A2 (en) *	1999-01-14	2000-07-20	Amylin Pharmaceuticals, Inc.	Methods for glucagon suppression
US7399489B2 (en) *	1999-01-14	2008-07-15	Amylin Pharmaceuticals, Inc.	Exendin analog formulations
PT1180121E (pt) *	1999-05-17	2004-03-31	Conjuchem Inc	Peptidos insulinotropicos de longa duracao
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
PL1745078T3 (pl) *	2004-04-23	2009-12-31	Conjuchem Biotechnologies Inc	Sposób oczyszczania koniugatów albumin
DE102004043153B4 (de) *	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
JP5755398B2 (ja) *	2005-03-18	2015-07-29	ノヴォノルディスクアー／エス	伸長されたｇｌｐ−１化合物
EP2004213A1 (en)	2006-04-03	2008-12-24	Novo Nordisk A/S	Glp-1 peptide agonists
AU2007240313B2 (en) *	2006-04-20	2012-02-02	Amgen Inc.	GLP-1 compounds
CN101125207B (zh) *	2006-11-14	2012-09-05	上海华谊生物技术有限公司	带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途

2009
- 2009-07-30 CN CN2009101655599A patent/CN101987868B/zh active Active
2010
- 2010-07-29 MX MX2012001186A patent/MX2012001186A/es active IP Right Grant
- 2010-07-29 BR BR112012001915-5A patent/BR112012001915B1/pt not_active IP Right Cessation
- 2010-07-29 US US13/388,056 patent/US20120129768A1/en not_active Abandoned
- 2010-07-29 ES ES10803913.2T patent/ES2694394T3/es active Active
- 2010-07-29 CN CN201080021344.0A patent/CN102421797B/zh active Active
- 2010-07-29 DK DK10803913.2T patent/DK2460825T3/en active
- 2010-07-29 AU AU2010278466A patent/AU2010278466B2/en not_active Ceased
- 2010-07-29 JP JP2012521950A patent/JP5768048B2/ja not_active Expired - Fee Related
- 2010-07-29 WO PCT/CN2010/075548 patent/WO2011012080A1/zh active Application Filing
- 2010-07-29 PL PL10803913T patent/PL2460825T3/pl unknown
- 2010-07-29 EP EP10803913.2A patent/EP2460825B1/en active Active
- 2010-07-29 RU RU2012105355/10A patent/RU2565536C2/ru active
- 2010-07-29 PT PT10803913T patent/PT2460825T/pt unknown
- 2010-07-29 CA CA2769229A patent/CA2769229C/en active Active
2011
- 2011-08-09 HK HK11108305.0A patent/HK1154027A1/xx unknown
2012
- 2012-01-12 ZA ZA2012/00239A patent/ZA201200239B/en unknown

Also Published As

Publication number	Publication date
CN101987868B (zh)	2013-09-04
EP2460825A1 (en)	2012-06-06
BR112012001915B1 (pt)	2019-11-12
US20120129768A1 (en)	2012-05-24
AU2010278466A1 (en)	2012-03-15
EP2460825A4 (en)	2014-03-19
DK2460825T3 (en)	2018-11-19
PT2460825T (pt)	2018-11-23
PL2460825T3 (pl)	2019-01-31
WO2011012080A1 (zh)	2011-02-03
ES2694394T3 (es)	2018-12-20
ZA201200239B (en)	2012-09-26
HK1154027A1 (en)	2012-04-20
CN102421797A (zh)	2012-04-18
MX2012001186A (es)	2012-06-27
AU2010278466B2 (en)	2014-10-30
JP2013500278A (ja)	2013-01-07
CA2769229A1 (en)	2011-02-03
CN102421797B (zh)	2014-12-31
CN101987868A (zh)	2011-03-23
RU2012105355A (ru)	2013-09-10
JP5768048B2 (ja)	2015-08-26
EP2460825B1 (en)	2018-08-22
RU2565536C2 (ru)	2015-10-20
CA2769229C (en)	2019-12-31

Publication	Publication Date	Title
BR112012001915A2 (pt)	2016-11-08	derivado de análogo de glp-1 ou seus sais farmacêuticos e seu uso.
BRPI1008045A2 (pt)	2016-03-15	derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BRPI1016150A2 (pt)	2016-04-19	compostos heterocíclicos e seus usos.
BRPI0918513A2 (pt)	2015-12-01	formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso
BRPI0915273A2 (pt)	2015-08-04	Derivado tricíclico inovador ou seus sais farmaceuticamente aceitáveis, seu método de preparação e composição farmacêutica que os contém.
BR112013025987A2 (pt)	2016-12-20	derivados de pirimidina para o tratamento de infecções virais
BR112012000660A2 (pt)	2016-11-16	compostos heterociclos e seus usos
BRPI0814267A2 (pt)	2015-03-31	Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI1008878A2 (pt)	2019-09-24	compostos heterocíclicos, composições farmacêuticas contendo os mesmos, e seus usos como inibidores de transportador de glicina 1
BRPI1014034A2 (pt)	2016-04-12	formulação e seu uso, composição, solução injetável e kit.
BRPI0920448A2 (pt)	2018-10-23	compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI0908225A2 (pt)	2016-11-01	derivados de piridazina e seu uso como agentes terapêuticos
BRPI0919810A2 (pt)	2017-10-31	compostos heterocíclicos contendo nitrogênio, sua preparação e seu uso como medicamentos antibacterianos
BR112012001061A2 (pt)	2016-03-29	glicosídeos 2,3-fluorados como inibidores de neuraminidase e seu uso como antivirais
BRPI0720124A2 (pt)	2014-03-04	Composições farmacêuticas e seus métodos de uso.
BR112013011693A2 (pt)	2016-08-09	derivados de ácido hidroxâmico e seu uso no tratamento de infecções por bactérias
BR112012004802A2 (pt)	2015-09-08	polipeptídeos tendo atividade oxirredutase e seus usos
BRPI0816372A2 (pt)	2015-02-24	Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0920183A2 (pt)	2018-05-22	derivados de fenetilamida e seus analogos heterociclicos
BR112012008044A2 (pt)	2019-09-24	pteridinas e seu uso como agroquímicos
BRPI1007413A2 (pt)	2015-08-25	Composição compreendendo ácido caftárico e/ou seus derivados
BRPI0915552A2 (pt)	2017-06-20	derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0814231A2 (pt)	2015-01-06	Derivados de pleuromutilina e seu uso como antimicrobianos
BRPI0817542A2 (pt)	2014-10-07	NOVOS INIBIDORES DE sEH E SEU USO
BRPI1013988A2 (pt)	2016-04-05	composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-01-29	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-06-11	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-09-17	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-11-12	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2010, OBSERVADAS AS CONDICOES LEGAIS
2024-05-21	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 14A ANUIDADE.
2024-09-10	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2785 DE 21-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.